Tolerability and pharmacokinetic analyses of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone sensitive prostate cancer (mHSPC) from ARASENS

被引：0

作者：

Tombal, B. ^{[1
]}

Smith, M. R. ^{[2
]}

Hussain, M. ^{[3
]}

Saad, F. ^{[4
]}

Fizazi, K. ^{[5
]}

Sternberg, C. N. ^{[6
]}

Crawford, E. D. ^{[7
]}

Kapur, S. ^{[8
]}

Zhang, W. ^{[9
]}

Ploeger, B. ^{[10
]}

Li, R. ^{[11
]}

Kuss, I. ^{[12
]}

Zieschang, C.

Wittemer-Rump, S.

Rezazadeh, Kalebasty A. ^{[13
]}

机构：

[1] Clin Univ St Luc, Dept Urol, Brussels, Belgium

[2] Massachusetts Gen Hosp Canc Ctr, Dept Oncol, Boston, MA USA

[3] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA

[4] Univ Montreal, Dept Urol, Hosp Ctr, Montreal, PQ, Canada

[5] Univ Paris Saclay, Inst Gustave Roussy, Villejuif, France

[6] Englander Inst Precis Med, Weill Cornell Dept Med, New York, NY USA

[7] Univ Calif San Diego, Dept Urol, Sch Med, San Diego, CA USA

[8] Bayer SEA, Dept Med Affairs, Singapore, Singapore

[9] Bayer Healthcare Pharmaceut Inc, Clin Pharmacol, Whippany, NJ USA

[10] Bayer AG, Clin Pharmacol, Berlin, Germany

[11] Bayer Healthcare Pharmaceut Inc, Dept Stat, Whippany, NJ USA

[12] Bayer AG, Clin Dev, Berlin, Germany

[13] Univ Calif Irvine, Div HematologyOncol, Orange, CA USA

来源：

EUROPEAN UROLOGY | 2023年 / 83卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

A1184

引用

页数：2

共 50 条

[1] Efficacy and safety of darolutamide (DARO) in combination with androgen-deprivation therapy (ADT) and docetaxel (DOC) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC) by metastatic burden: Subgroup analyses of ARASENS
Tombal, B.
Saad, F.
Fizazi, K.
Sternberg, C. N.
Crawford, E. D.
Gratzke, C.
Grabbert, M.
Vilaseca, A.
Shore, N.
Kopyltsov, E.
Boegemann, M.
Kapur, S.
Srinivasan, S.
Verholen, F.
Kuss, I.
Joensuu, H.
Smith, M. R.
Hussain, M.
EUROPEAN UROLOGY, 2023, 83
[2] Dosing, safety, and pharmacokinetics (PK) of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) in the ARASENS study
Kalebasty, Arash Rezazadeh
Hammerer, Peter
Tombal, Bertrand
Hussain, Maha
Saad, Fred
Fizazi, Karim
Sternberg, Cora N.
Crawford, David
Zhang, Weijiang
Ploeger, Bart
Li, Rui
Kuss, Iris
Zieschang, Carsten
Wittemer-Rump, Sabine
Smith, Mathew
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 80 - 81
[3] Dosing, safety, and pharmacokinetics (PK) of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) in the ARASENS study.
Rezazadeh, Arash
Tombal, Bertrand F.
Hussain, Maha H. A.
Saad, Fred
Fizazi, Karim
Sternberg, Cora N.
Crawford, E. David
Kapur, Shivani
Zhang, Weijiang
Ploeger, Bart
Li, Rui
Kuss, Iris
Zieschang, Carsten
Wittemer-Rump, Sabine
Smith, Matthew Raymond
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[4] Darolutamide (DARO) in combination with androgendeprivation therapy (ADT) and docetaxel (DOC) in Chinese patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) in the phase III ARASENS study
Wang, S.
Fu, C.
Li, Y.
Xing, J.
Zhou, L.
Yang, Y.
Wang, H.
Smith, M. R.
Tombal, B.
Hussain, M.
Niu, Y.
Cai, L.
Liu, Q.
Littleton, N.
Li, R.
Ye, D.
ANNALS OF ONCOLOGY, 2023, 34 : S1572 - S1572
[5] Prostate-specific antigen (PSA) outcomes with darolutamide (DARO): Androgen-deprivation therapy (ADT) and docetaxel (DOC) in patients (pts) with high- and low-volume metastatic hormone-sensitive prostate cancer (mHSPC) in ARASENS
Saad, F.
Hussain, M.
Tombal, B.
Fizazi, K.
Sternberg, C. N.
Crawford, E. D.
Boegemann, M.
Tutrone, R.
Littleton, N.
Srinivasan, S.
Verholen, F.
Kuss, I.
Smith, M. R.
ANNALS OF ONCOLOGY, 2023, 34 : S964 - S964
[6] Efficacy and Safety of Darolutamide (DARO) in Combination with Androgen-Deprivation Therapy (ADT) and Docetaxel (DOC) by Disease Volume and Risk in the Phase 3 ARASENS Study
Hussain, Maha
Boegemann, Martin
Tombal, Bertrand
Saad, Fred
Fizazi, Karim
Sternberg, Cora N.
Crawford, David
Shore, Neal
Kopyltsov, Evgeny
Kalebasty, Arash Rezazadeh
Ye, Dingwei
Cruz, Felipe Jose
Suzuki, Hiroyoshi
Srinivasan, Shankar
Verholen, Frank
Kuss, Iris
Joensuu, Heikki
Smith, Mathew
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 80 - 80
[7] ARASENS Trial: Should darolutamide now be added to androgen-deprivation therapy and docetaxel in patients with metastatic, hormone-sensitive prostate cancer?
Kumar, Naveen
INDIAN JOURNAL OF UROLOGY, 2022, 38 (03) : 238 - 239
[8] COMBINATION OF DAROLUTAMIDE WITH ANDROGEN-DEPRIVATION THERAPY AND DOCETAXEL INCREASES SURVIVAL FOR PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER IN THE PHASE 3 ARASENS STUDY
Olivier, Kara
Tombal, Betrand
Thiele, Silke
Li, Rui
Joensuu, Heikki
Smith, Matthew
ONCOLOGY NURSING FORUM, 2022, 49 (02) : 20 - 20
[9] Efficacy and safety of darolutamide (DARO) in combination with androgen-deprivation therapy (ADT) and docetaxel (DOC) by disease volume and disease risk in the phase 3 ARASENS study.
Hussain, Maha H. A.
Tombal, Bertrand F.
Saad, Fred
Fizazi, Karim
Sternberg, Cora N.
Crawford, E. David
Shore, Neal D.
Kopyltsov, Evgeny
Rezazadeh, Arash
Boegemann, Martin
Ye, Ding-Wei
Cruz, Felipe Melo
Suzuki, Hiroyoshi
Kapur, Shivani
Srinivasan, Shankar
Verholen, Frank
Kuss, Iris
Joensuu, Heikki
Smith, Matthew Raymond
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[10] Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk in the Phase 3 ARASENS Study
Hovey, Elizabeth
Hussain, Maha
Tombal, Bertrand
Saad, Fred
Fizazi, Karim
Sternberg, Coran
Crawford, E. David
Shore, Neal
Kopyltsov, Evgeny
Rezazadeh Kalebasty, Arash
Bogemann, Martin
Ye Dingwei
Cruz, Felipe
Suzuki, Hiroyoshi
Verholen, Frank
Srinivasan, Shankar
Kuss, Iris
Joensuu, Heikki
Smith, Matthew R.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2023, 19 : 64 - 64

← 1 2 3 4 5 →